Ovarian Cancer

Metastatic Ovarian Carcinoma

Female, 57 years

Patient Internal ID: 273984642

ICD-10 code

C56 Malignant Neoplasm of Ovary

Diagnosis (Incl. Metastases/Stage) and Year

March 2010
Ovarian Carcinoma pT3aNxM0 G2 stage 3A, BRCA (-). Disease progression in 2012, Metastasis in Peritoneum, Disease progression in 2021 – Metastatic Lymph nodes in Rectal Region.

Previous Treatment

Surgery, Radiation Therapy, Chemotherapy (Carboplatin and Cyclophosphamide), Surgery, Intraperitoneal Chemotherapy (Paclitaxel and Cisplatin), Surgery, Chemotherapy (Paclitaxel and Cisplatin), Surgery (HIPEC), Chemotherapy (Carboplatin and Gemcitabine), Chemotherapy (Liposomal Doxorubicin and Carboplatin), Chemotherapy (Paclitaxel and Carboplatin), Chemotherapy (Paclitaxel and Carboplatin), Chemotherapy (Topotecan), Radiation Therapy, Chemotherapy (Vinorelbine).

Prognosis and Survival Expectation

The Metastatic Ovarian Cancer prognosis remains poor, with a median survival of ~32 months from diagnosis. The average relative 5-year survival rate for Distant Spread Ovarian Cancer is about 31%.

Treatment Provided

Autologous DCV (8 doses) and CIK (4 doses) over a period of 8 months. Additionally, the patient received Umbilical Cord Blood Derived NK cells (9 doses).

Patient Survival/Condition and Year
Date of Review: 14/12/2023

The patient has survived for 11 years since the disease progression and continues to receive Chemotherapy. It can be concluded that the addition of Immunotherapy, alongside Surgery, Chemotherapy and Radiation Therapy, has extended patient survival by an estimate of around 8 years so far.